Pharmacological blockage of the AHR-CYP1A1 axis: a call for in vivo evidence

Area of Science:

• Pharmacology
• Molecular Biology
• Immunology

Background:

• The aryl hydrocarbon receptor (AHR) is a transcription factor activated by various environmental and metabolic compounds.
• AHR pathway modulation is implicated in chronic diseases, suggesting therapeutic potential for its abrogation.
• Current research on AHR antagonists is primarily in vitro, necessitating in vivo validation.

Purpose of the Study:

• To review the pharmacodynamic and pharmacokinetic properties of AHR antagonists and CYP1A1 inhibitors.
• To provide guidance for in vivo rodent studies targeting the AHR pathway.
• To highlight the emerging therapeutic potential of AHR inhibition in chronic diseases.

Main Methods:

• Literature review of in vivo studies in rodent models (mice and rats).
• Analysis of pharmacodynamic and pharmacokinetic data for AHR antagonists and CYP1A1 inhibitors.
• Synthesis of current knowledge on AHR-targeted therapies.

Main Results:

• Compilation of existing data on AHR antagonists and CYP1A1 inhibitors in preclinical models.
• Identification of key considerations for designing in vivo studies.
• Overview of the therapeutic landscape for AHR-targeted interventions.

Conclusions:

• Pharmacological targeting of the AHR pathway, particularly through antagonists and CYP1A1 inhibitors, is a promising therapeutic strategy.
• In vivo studies are crucial for advancing AHR-targeted therapies for metabolic and inflammatory diseases.
• The field is rapidly evolving, with AHR antagonists entering clinical trials.